Compare Riot Platforms Inc (RIOT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Riot Platforms Inc vs Recursion Pharmaceuticals Inc — how do they compare? Riot Platforms Inc trades at $21.79 (market cap $8.29B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B). The key difference: Riot Platforms Inc is far larger — about 4.8× Recursion Pharmaceuticals Inc's market cap, and Riot Platforms Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RIOT | RXRX | |
|---|---|---|
Market Cap | $8.29B | $1.74B |
Sector | Technology | Health |
52-Week High | $28.67 | $6.79 |
52-Week Low | $11.83 | $2.84 |
Enterprise Value | $8.69B | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Riot Platforms (RIOT) trades at $22.26, up 2.11% with a bullish technical signal. The stock shows strong analyst support with 94.7% buy ratings and a $33.00 consensus price target, representing 48% upside potential. Recent news highlights a transformative $9.1 billion, 20-year AI data center deal with Anthropic, shifting the company's focus from Bitcoin mining to high-margin AI infrastructure. However, fundamental challenges persist with negative net income margins and consecutive earnings misses.
The outlook balances transformative AI opportunities against current financial weakness. The Anthropic partnership provides long-term revenue visibility but execution risks remain high. With negative profitability and cash flow challenges, investors must weigh the company's AI transition potential against its current financial instability in a volatile market environment.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
